Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

Bibliographic Details
Title:	Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting
Authors:	Qiling Bu, Hong-Hu Zhu, Wenming Chen
Source:	Journal of Hematology & Oncology, Vol 18, Iss 1, Pp 1-4 (2025)
Publisher Information:	BMC, 2025.
Publication Year:	2025
Collection:	LCC:Diseases of the blood and blood-forming organs LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms:	Immunoglobulin light chain amyloidosis, Targeted therapies, Clinical trials, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details:	Abstract Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1756-8722
Relation:	https://doaj.org/toc/1756-8722
DOI:	10.1186/s13045-025-01681-7
Access URL:	https://doaj.org/article/bccc0410dde64468b5ae854d010bf5fc
Accession Number:	edsdoj.bccc0410dde64468b5ae854d010bf5fc
Database:	Directory of Open Access Journals
Full text is not displayed to guests.	Login for full access.

More Details
ISSN:	17568722
DOI:	10.1186/s13045-025-01681-7
Published in:	Journal of Hematology & Oncology
Language:	English